Ascend Capital’s Gilead Sciences GILD Stock Holding History

Ascend Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$9.61M	Sell	124,510 -96,434	-44%	-$7.28M	0.48%	68
2018 Q2	$15.7M	Sell	220,944 -213,577	-49%	-$15.1M	0.74%	46
2018 Q1	$32.8M	Buy	+434,521	New	+$34.5M	1.33%	21
2016 Q3	–	Sell	-304,143	Closed	-$25.4M	–	137
2016 Q2	$25.4M	Buy	+304,143	New	+$27M	1.66%	14
2016 Q1	–	Sell	-120,000	Closed	-$12.1M	–	118
2015 Q4	$12.1M	Buy	+120,000	New	+$12.5M	0.43%	74
2015 Q1	–	Sell	-513,858	Closed	-$48.4M	–	184
2014 Q4	$48.4M	Buy	+513,858	New	+$53.1M	1.86%	11
2014 Q1	–	Sell	-97,150	Closed	-$7.3M	–	203
2013 Q4	$7.3M	Sell	97,150 -2,592	-3%	-$180K	0.22%	119
2013 Q3	$6.27M	Sell	99,742 -168,955	-63%	-$10.1M	0.23%	118
2013 Q2	$13.8M	Buy	+268,697	New	+$14M	0.59%	55

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ascend Capital's GILD Position: Q3 2018 in Review

Ascend Capital reduced its Gilead Sciences (GILD) stake by 44% in Q3 2018, selling an estimated $7.28M and leaving 124,510 shares worth $9.61M. The position accounts for 0.48% of the portfolio, ranked #68.

Ascend Capital first reported a position in GILD in Q2 2013 and has held it in 9 quarters since. The position peaked at $48.4M in Q4 2014. 1,527 funds tracked by Wall St. Rank hold GILD as of Q3 2018.

Ascend Capital held 124,510 shares of Gilead Sciences worth $9.61M as of Q3 2018.
Ascend Capital sold 96,434 Gilead Sciences shares in Q3 2018, an estimated $7.28M.
Gilead Sciences made up 0.48% of Ascend Capital's portfolio in Q3 2018, its #68 holding.
Ascend Capital first reported a position in Gilead Sciences in Q2 2013 and has held it in 9 quarters since.
Ascend Capital's Gilead Sciences position peaked at $48.4M in Q4 2014.
1,527 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.